Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Banchi

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Medicine|October 29, 2025
Pharmacokinetics and Monitoring of Methotrexate in Adults with Acute Lymphoblastic Leukaemia: A 10-Year Follow-Up at an Italian CentrePasquale Fabio Calabrò, Letizia Biso, Marianna Lastella, et al.
Biochemical Pharmacology|April 7, 2019
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamicsTeresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.
American Journal of Cancer Research|August 15, 2022
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancerLorenzo Fornaro, Gianna Musettini, Paola Orlandi, et al.
Journal of Clinical Medicine|November 25, 2023
Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. <i>J. Clin. Med.</i> 2022, <i>11</i>, 7162Guido Bocci, Sabrina Pelliccia, Paola Orlandi, et al.
Journal of Clinical Medicine|December 11, 2022
Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell LymphomaGuido Bocci, Sabrina Pelliccia, Paola Orlandi, et al.
Biochemical Pharmacology|November 30, 2023
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenibPaola Orlandi, Marta Banchi, Francesca Vaglini, et al.
NPJ Breast Cancer|March 22, 2022
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patientsLuigi Coltelli, Giacomo Allegrini, Paola Orlandi, et al.
Oncology Research|May 1, 2026
Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall SurvivalLuigi Coltelli, Paola Orlandi, Chiara Finale, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Medicine|October 29, 2025
Pharmacokinetics and Monitoring of Methotrexate in Adults with Acute Lymphoblastic Leukaemia: A 10-Year Follow-Up at an Italian CentrePasquale Fabio Calabrò, Letizia Biso, Marianna Lastella, et al.
Biochemical Pharmacology|April 7, 2019
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamicsTeresa Di Desidero, Paola Orlandi, Anna Fioravanti, et al.
American Journal of Cancer Research|August 15, 2022
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancerLorenzo Fornaro, Gianna Musettini, Paola Orlandi, et al.
Journal of Clinical Medicine|November 25, 2023
Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. <i>J. Clin. Med.</i> 2022, <i>11</i>, 7162Guido Bocci, Sabrina Pelliccia, Paola Orlandi, et al.
Journal of Clinical Medicine|December 11, 2022
Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell LymphomaGuido Bocci, Sabrina Pelliccia, Paola Orlandi, et al.
Biochemical Pharmacology|November 30, 2023
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenibPaola Orlandi, Marta Banchi, Francesca Vaglini, et al.
NPJ Breast Cancer|March 22, 2022
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patientsLuigi Coltelli, Giacomo Allegrini, Paola Orlandi, et al.
Oncology Research|May 1, 2026
Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall SurvivalLuigi Coltelli, Paola Orlandi, Chiara Finale, et al.
Pageof 3